Metsera | search
Click here to view Metsera news from 60+ newspapers.
Bookmark or Share- MetseraMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases.
- Arch-backed obesity biotech launches with $290MClinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's an almost...
- GLP-1 start-up Metsera launches with $290 millionMetsera is advancing a suite of peptide and peptide-antibody conjugate drugs for weight loss and other indications, all based on GLP-1 agonists.
- Metsera weight-loss startup wants to compete with Novo and Lilly - Fast ...Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of...
- Metsera Launches to Lead the Next Generation of Medicines for Obesity ...Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...
More
